The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1592
ISSUE1592
February 24, 2020
Drugs for Depression
| Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Drugs for Depression
February 24, 2020 (Issue: 1592)
Complete remission of symptoms is the goal of
treatment for major depressive disorder; a partial
response is associated with an increased risk of
relapse. Improvement in symptoms can occur within
the first two weeks of treatment with an...more
- American Psychiatric Association. Treating major depressive disorder: a quick reference guide. Based on practice guideline for the treatment of patients with major depressive disorder third edition 2010. Available at http://bit.ly/2GTfF02. Accessed February 13, 2020.
- A Cipriani et al. Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents: a network meta-analysis. Lancet 2016; 388:881.
- CE Angermann et al. Effect of escitalopram on all-cause mortality and hospitalization in patients with heart failure and depression: the MODD-HF randomized clinical trial. JAMA 2016; 315:2683.
- SS Hedayati et al. Effect of sertraline on depressive symptoms in patients with chronic kidney disease without dialysis dependence: the CAST randomized clinical trial. JAMA 2017; 318:1876.
- CP Walther et al. Treating depression in patients with advanced CKD: beyond the generalizability frontier. JAMA 2017; 318:1873.
- MD Waldinger. Psychiatric disorders and sexual dysfunction. Handb Clin Neurol 2015; 130:469.
- Citalopram, escitalopram and the QT interval. Med Lett Drugs Ther 2013; 55:59.
- MC Funk et al. APA resource document. Resource document on QTc prolongation and psychotropic medications approved by the Joint Reference Committee, June 2018.
- R Gafoor et al. Antidepressant utilisation and incidence of weight gain during 10 years' follow-up: population based cohort study. BMJ 2018; 361:k1951.
- VM Pereira et al. Bupropion in the depression-related sexual dysfunction: a systematic review. CNS Neurol Disord Drug Targets 2014; 13:1079.
- KR Connolly and ME Thase. If at first you don't succeed: a review of the evidence for antidepressant augmentation, combination and switching strategies. Drugs 2011; 71:43.
- MH Trivedi et al. Medication augmentation after the failure of SSRIs for depression. N Engl J Med 2006; 354:1243.
- Vilazodone (Viibryd) – a new antidepressant. Med Lett Drugs Ther 2011; 53:53.
- Vortioxetine (Trintellix) for depression. Med Lett Drugs Ther 2013; 55:93.
- Transdermal selegiline (Emsam). Med Lett Drugs Ther 2006; 48:41.
- C Caddy et al. Ketamine and other glutamate receptor modulators for depression in adults. Cochrane Database Syst Rev 2015; 9:CD011612.
- K Bozymski et al. Esketamine: A novel option for treatment-resistant depression. Ann Pharmacother 2019 Dec 4 (epub).
- Esketamine nasal spray (Spravato) for treatment-resistant depression. Med Lett Drugs Ther 2019; 61:54.
- Adjunctive antipsychotics for major depression. Med Lett Drugs Ther 2011; 53:74.
- BM Wright et al. Augmentation with atypical antipsychotics for depression: a review of evidence-based support from the medical literature. Pharmacotherapy 2013; 33:344.
- M Hobart et al. A long-term, open-label study to evaluate the safety and tolerability of brexpiprazole as adjunctive therapy in adults with major depressive disorder. J Clin Psychopharmacol 2019; 39:203.
- Brexpiprazole (Rexulti) for schizophrenia and depression. Med Lett Drugs Ther 2015; 57:116.
- MB Stein and J Sareen. Clinical practice. Generalized anxiety disorder. N Engl J Med 2015; 373:2059.
- M Fornaro et al. The FDA "Black Box" warning on antidepressant suicide risk in young adults: more harm than benefits? Front Psychiatry 2019; 10:294.
- J March et al. Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents with Depression Study (TADS) randomized controlled trial. JAMA 2004; 292:807.
- RD Gibbons et al. The relationship between antidepressant prescription rates and rate of early adolescent suicide. Am J Psychiatry 2006; 163:1898.
- NA Buckley et al. Serotonin syndrome. BMJ 2014; 348:g1626.
- EW Boyer and M Shannon. The serotonin syndrome. N Engl J Med 2005; 352:1112.
- FDA. Drug Safety Communication: FDA warns about several safety issues with opioid pain medicines; requires label changes. March 22, 2016. Available at: http://bit.ly/3bulrDo. Accessed February 13, 2020.
- R Jain et al. Good, better, best: clinical scenarios for the use of L-methylfolate in patients with MDD. CNS Spectr 2019 Dec 13 (epub).
- L-Methylfolate (Deplin) for depression and schizophrenia. Med Lett Drugs Ther 2010; 52:31.
- RC Shelton. St. John's wort (Hypercum perforatum) in major depression. J Clin Psychiatry 2009; 70 (suppl 5):23.
- Inhibitors and inducers of CYP enzymes and P-glycoprotein. Med Lett Drugs Ther 2019 November 6 (epub). Available at: medicalletter.org/downloads/CYP_PGP_Tables.pdf.
- O Stephansson et al. Selective serotonin reuptake inhibitors during pregnancy and risk of stillbirth and infant mortality. JAMA 2013; 309:48.
- A Bérard et al. Paroxetine use during pregnancy and perinatal outcomes including types of cardiac malformations in Quebec and France: a short communication. Curr Drug Saf 2012; 7:207.
- H Malm et al. Pregnancy complications following prenatal exposure to SSRIs or maternal psychiatric disorders: results from population-based national register data. Am J Psychiatry 2015; 172:1224.
- S Gentile. On categorizing gestational, birth, and neonatal complications following late pregnancy exposure to antidepressants: the prenatal antidepressant exposure syndrome. CNS Spectr 2010; 15:167.
- CD Chambers et al. Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N Engl J Med 2006; 354:579.
- C Bellantuono et al. The safety of serotonin-noradrenaline reuptake inhibitors (SNRIs) in pregnancy and breastfeeding: a comprehensive review. Hum Psychopharmacol 2015; 30:143.
- U Winterfeld et al. Pregnancy outcome following maternal exposure to mirtazapine: a multicenter, prospective study. J Clin Psychopharmacol 2015; 35:250.
- LH Pedersen. The safety of antidepressant in pregnancy: maternal antidepressants are implicated in ADHD, but so is maternal depression. BMJ 2017; 357:j2544.
- K Grove et al. Prenatal antidepressant exposure and child motor development: a meta-analysis. Pediatrics 2018; 142:e20180356.
- T Boukhris et al. Antidepressant use during pregnancy and the risk of autism spectrum disorder in children. JAMA Pediatr 2016; 170:117.
- Brexanolone (Zulresso) for postpartum depression. Med Lett Drugs Ther 2019; 61:68.
- JG Powell et al. Brexanolone (Zulresso): finally, an FDA-approved treatment for postpartum depression. Ann Pharmacother 2020; 54:157.
- Approximate WAC. WAC = wholesaler acquisition cost or manufacturer's published price to wholesalers; WAC represents a published catalogue or list price and may not represent an actual transactional price. Source: AnalySource® Monthly. February 5, 2020. Reprinted with permission by First Databank, Inc. All rights reserved. ©2020. www.fdbhealth.com/drug-pricing-policy.
- PE Holtzheimer and HS Mayberg. Neuromodulation for treatment-resistant depression. F1000 Med Rep 2012; 4:22.
- Health Quality Ontario. Repetitive transcranial magnetic stimulation for treatment-resistant depression: a systematic review and meta-analysis of randomized controlled trials. Ont Health Technol Assess Ser 2016; 16:1.
- IO Bergfeld. Deep brain stimulation of the ventral anterior limb of the internal capsule for treatment-resistant depression: a randomized clinical trial. JAMA Psychiatry 2016; 73:456.
- DD Dougherty. A randomized sham-controlled trial of deep brain stimulation of the ventral capsule/ventral striatum for chronic treatment-resistant depression. Biol Psychiatry 2015; 78:240.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
Would you like to read the rest of this article? Gain access below.
Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App for iOS, Android, and Kindle Fire
- FREE online per issue CME/CE
Purchase this article:
Title: Drugs for Depression
Article code: 1592a
Article code: 1592a
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.